Literature DB >> 35701769

Factors influencing warm ischemia time in robot-assisted partial nephrectomy change depending on the surgeon's experience.

Kazuyuki Numakura1, Mizuki Kobayashi2, Atsushi Koizumi2, Soki Kashima2, Ryohei Yamamoto2, Taketoshi Nara2, Mitsuru Saito2, Shintaro Narita2, Takamitsu Inoue3, Tomonori Habuchi2.   

Abstract

INTRODUCTION: Warm ischemia time (WIT) is a primary concern for robot-assisted laparoscopic partial nephrectomy (RALPN) patients because longer WIT is significantly associated with postoperative deteriorating kidney function. Tumor complexity, determined by the RENAL nephrometry score (RENAL score), can help predict surgical outcomes, but it is unclear what RENAL score and clinical factors affect WIT. This study explored the clinical factors predicting long WIT in experienced surgeon to RALPN.
MATERIALS AND METHODS: In our institute, 174 RALPNs were performed between November 2013 and February 2021, of which 114 were performed by a single surgeon and included in this study. Clinical staging and the total RENAL score were determined based on preoperative CT scans. The cases were divided into three groups based on experience: period 1: 1-38, period 2: 39-76, and period 3: 77-114. The clinical factors associated with longer WIT were analyzed per period.
RESULTS: The overall median tumor diameter was 32 mm, and one patient had a positive surgical margin, but there were no cancer-related deaths. In total, there were 18 complications (15.8%). Periods 2 and 3 had larger tumor diameters (p < 0.01) and worse preoperative kidney function (p = 0.029) than period 1. A RENAL L-component score of 3 was associated with longer WIT in period 3 (odds ratio: 3.900; 95% confidence interval: 1.004-15.276; p = 0.044), but the tumor diameter and the total RENAL score were not.
CONCLUSIONS: A large tumor in the central lesion indicated by the RENAL L-component score was associated with increased WIT in RALPN.
© 2022. The Author(s).

Entities:  

Keywords:  Kidney; Oncology; RENAL score; Robotic surgery

Mesh:

Year:  2022        PMID: 35701769      PMCID: PMC9199197          DOI: 10.1186/s12957-022-02669-0

Source DB:  PubMed          Journal:  World J Surg Oncol        ISSN: 1477-7819            Impact factor:   3.253


Introduction

After the introduction of the robotic platform for kidney surgery, robot-assisted laparoscopic partial nephrectomy (RALPN) for T1 renal cell carcinoma (RCC) became a standard procedure [1, 2]. There are obvious advantages to robotic surgery over pure laparoscopic nephrectomies, such as more precise resections and proper parenchyma suturing [3]. The robotic procedure also achieves good oncological outcomes, preserves more kidney function, and avoids complications [4]. A trifecta of RALPN was defined as warm ischemia time (WIT) ≤ 25 min, negative surgical margins, and no postoperative complications ≥ grade 2. This is a useful evaluation method for assuring good clinical outcomes in RALPN patients [5]. Of the three factors, WIT should be the most concerning because positive surgical margins and severe complications are quite rare. Moreover, a longer WIT is a major factor associated with deteriorating kidney function [6] and potentially leading to worse survival rates due to chronic kidney disease and cardiovascular disease [7]. The RENAL nephrometry score (radius [tumor size], exophytic/endophytic properties, nearness of the tumor to the collecting system, anterior/posterior, location relative to the polar line; RENAL score) is used to predict surgical difficulty in RALPN and laparoscopic partial nephrectomy patients [8]. However, it remains unclear what RENAL score or other clinical factors affect WIT in RALPN [9, 10]. Since most previous studies assessed a predicting factor of WIT only depending on dividing patients into groups by clinical factors and/or surgical techniques, a real factor could be covered up due to many confounders [11-13]. To minimize this influence, we assessed WIT by dividing patients into three chronological periods, which could reflect a learning curve [14], in the same surgical procedure by a single surgeon. This study aimed to delineate clinical factors predicting longer WIT during RALPN.

Materials and methods

Between November 2013 and February 2021, six surgeons performed 174 RALPNs for clinical T1 kidney tumors in our institute. Of these, 114 RALPNs were performed by a single surgeon (T.H.) and were analyzed in this study. The clinical staging and the RENAL score were determined based on CT scans. RALPN was performed using standard transperitoneal or retroperitoneal approaches depending on the patient’s history of trans-abdominal surgery, the tumor size, and the tumor location. We did not use a ureteral catheter [15]. Partial nephrectomy was performed by clamping the main trunk of a renal artery(s) with a bulldog clamp. In renal hilar tumors, a renal vein was also clamped. Tumors with a 5-mm surgical margin were resected under 15 mm Hg CO2 pressure, while the preparation, renal capsule, and tumor surface were exposed under 10 mm Hg CO2 pressure. The inner medullary hemostatic sutures were performed by a running barbed suture, followed by early unclamping and additional hemostatic sutures. Both the inner- and outer-layer renorrhaphy were performed by 2-0 STRATAFIXTM Spiral PDSTM Plus (Ethicon, USA) or 3-0 V-LocTM (Medtronic, Ireland), according to the tumor size and location. All specimens were removed using an ENDOPOUCHTM RETRIEVERTM Specimen bag (AutoSuture, UK) through a camera port. Intra- and postoperative complications were categorized based on the Satava [16] and the Clavien-Dindo [17] classification systems, respectively, into major or minor complications; major complications were defined as grade II or higher. To assess clinical risk factors for prolonged WIT, the patients were divided into three groups based on the number of RALPNs in chronological order (period 1: cases 1–38, period 2: cases 39–76, and period 3: cases 77–114).

Ethics statement

All procedures were performed according to the tenets of the 1964 Declaration of Helsinki. This study consisted of a retrospective chart review. Informed consent was received for all the participating patients. Research involving human participants was supervised and approved by the Ethics Board of the Akita University Hospital.

Statistics analysis

All data were expressed as the median (range). The clinical risk factors associated with a longer WIT were screened by univariate analysis. The factors with a p-value of < 0.1 in the univariate analysis were confirmed by logistic regression analysis. All p-values were two-sided, and p < 0.05 was considered statistically significant. All statistical analyses were performed using SPSS version 26.0 statistical software (SPSS Japan Inc., Tokyo, Japan).

Data availability statement

The data presented in this study are available on request from the corresponding author.

Results

Tables 1 and 2 present the clinicopathological characteristics of all enrolled patients. The tumor diameter increased with each period (median; 25.7 mm vs. 33.9 mm vs. 38.9 mm, p < 0.01), but there was no difference in WIT (17.2 min vs. 18.4 min vs. 17.4 min, p = 0.666). This is perhaps because the indications for tumor diameter and kidney function extended with increasing surgical experience. In period 1, only one patient (2.6%) had a tumor stage higher than Ib, but the incidence rate increased in period 2 (8 patients, 21.1%) and period 3 (18 patients, 47.4%) (p < 0.01 [chi-squared test]). There was no difference in the complication rate among periods (all periods: 6 incidences, 15.8%, p = 1.000). Risk factors for longer WIT were screened per period by dividing the groups by the median WIT (17.2 min; Supplementary Table 1). Logistic regression analysis confirmed that male patients (odds ratio [OR], 6.182; 95% confidence interval [CI], 1.101–34.700; p = 0.038) and a RENAL N-component score of 3 (OR, 6.500; 95% CI, 1.127–34.484; p = 0.036) were significantly associated with longer WIT in period 1 (Table 3). In period 2, tumors larger than 33 mm (OR, 6.500; 95% CI, 1.537–27.486; p = 0.011), a RENAL N-component score of 3 (OR, 5.000; 95% CI, 1.096–22.820; p = 0.038), and a total RENAL score of 8 or more (OR, 4.667; 95% CI, 1.187–18.352; p = 0.027) were significantly associated with longer WIT (Table 3). In period 3, a RENAL L-component score of 3 was significantly associated with longer WIT (OR, 3.900; 95% CI, 1.004–15.276; p = 0.044; Table 3), but the tumor diameter and the total RENAL score were not (Supplementary Table 1).
Table 1

Patient characteristics

All casesAll cases by TH1st period2nd period3rd period
N = 174N = 114N = 38N = 38N = 38
Age, years (median [IQR])64 (56–70)64 (58–70)62.4 (58–68)65.5 (59–70)64 (55–70)
Sex (%)Male129 (74.1)85 (74.6)28 (73.7)32 (84.2)25 (65.8)
Female45 (25.9)29 (25.4)10 (26.3)6 (15.8)13 (34.2)
BMI, kg/m2 (median [IQR])24.5 (22.5–26.7)24.4 (22.0–26.6)24.2 (21.5–25.5)24.6 (22.5–27.4)24.6 (21.1–26.7)
Laterality (%)Right107 (61.5)69 (60.5)26 (68.4)26 (68.4)17 (44.7)
Left67 (38.5)45 (39.5)12 (31.6)12 (31.6)21 (55.3)
Diameter, mm (median [IQR])29 (22–35)32 (25–41)26 (20–30)33.5 (27–42)39.5 (30–47)
RENAL nephrometry score (median [IQR])7 (5–8)7 (5–8)5 (4–7)7 (6–8)8 (7–9)
R (median [IQR])1 (1–1)1 (1–1)1 (1–1)1 (1–1)1 (1–2)
E (median [IQR])2 (1–2)2 (1–2)1 (1–2)2 (1–2)2 (1–2)
N (median [IQR])2 (1–3)3 (1–3)1 (1–3)3 (2–3)3 (3–3)
L (median [IQR])1 (1–3)1 (1–3)1 (1–2)2 (1–3)2 (1–3)
Preoperative eGFR, mL/min (median [IQR])67.6 (55.8–75.5)69.4 (58.7– 76.4)75.2 (65.2–78.0)64.7 (55.7–75.0)68.2 (54.1–75.8)
POM 1 eGFR, mL/min (median [IQR])63.4 (52.5–75.9)63.9 (53.9–77.5)67.9 (62.2–82.2)64.9 (52.8–7.3)55.4 (46.7–67.6)
Clinical T (%)1a147 (84.5)87 (76.3)37 (97.4)30 (78.9)20 (52.6)
1b27 (15.5)27 (23.7)1 (2.6)8 (21.1)18 (47.4)

IQR interquartile range; BMI body mass index; RENAL radius, exophytic/endophytic, nearness of tumor to collecting system, anterior/posterior, location relative to polar line; eGFR estimated glomerular filtration rate; POM postoperative month; T size of the primary tumor and whether it has invaded nearby tissue; TH high-volume surgeon in our hospital

Table 2

Surgical outcomes of robot-assisted partial nephrectomy

All casesAll cases by HT1st period2nd period3rd period
Median (range)N = 174N = 114N = 38N = 38N = 38
Approach (%)Transperitoneal114 (65.5)69 (60.5)31 (81.6)27 (71.1)11 (28.9)
Retroperitoneal60 (34.5)45 (39.5)7 (18.4)11 (28.9)27 (71.1)
Operative time (min)221 (140–399)223 (140–353)197.5 (140–353)231 (153–290)239.5 (174–328)
Operator61111
Console time (min)All cases143 (42–277)138.5 (42–277)140.5 (64–203)142 (74–200)136.5 (42–277)
Transperitoneal157 (42–262)
Retroperitoneal113 (58–277)
Estimated blood loss (mL)42 (0–1805)60 (0–1805)63 (0–1805)50.5 (0–1184)74.5 (0–736)
Warm ischemia time (min)17.3 (9.2–56)17.2 (9.2–56.0)17.4 (9.3–34.0)16.9 (10.1–56.0)17.3 (10.9–29.2)
Intra-operative complication (%)Satava ≥ 23 (1.7)1 (0.9)1 (2.6)0 (0)0 (0)
Postoperative complication (%)Clavien-Dindo ≥ 227 (15.5)17 (14.9)5 (13.2)6 (15.8)6 (15.8)
Positive surgical margin (%)1 (0.6)1 (0.9)1 (2.6)0 (0)0 (0)
eGFR at 1 month after operation (%)≥ 90%121 (69.5)73 (64.0)29 (76.3)28 (73.7)16 (42.1)
Trifecta accomplishment (%)151 (86.8)100 (87.7)33 (86.8)32 (84.2)35 (92.1)
Histology (%)Clear128 (73.6)84 (73.7)27 (71.1)33 (86.8)24 (63.2)
Papillary22 (12.6)14 (12.3)4 (10.5)3 (7.9)7 (18.4)
Chromophobe9 (5.2)7 (6.1)2 (5.3)2 (5.3)3 (7.9)
AML7 (4.0)5 (4.4)3 (7.9)0 (0)2 (5.3)
Oncocytoma3 (1.7)3 (2.6)2 (5.3)0 (0)1 (2.6)
Xp11.21 (0.6)1 (0.9)0 (0)0 (0)1 (2.6)
MTSCC1 (0.6)0 (0)0 (0)0 (0)0 (0)
Pathological T (%)1a145 (83.3)90 (78.9)31 (81.6)33 (86.8)26 (68.4)
1b15 (8.6)14 (12.3)1 (2.6)5 (13.2)8 (21.1)
3a2 (1.1)2 (1.8)1 (2.6)0 (0)1 (2.6)

HT high-volume surgeon in our hospital; eGFR estimated glomerular filtration rate; AML angiomyolipoma; MTSCC mucinous tubular and spindle cell carcinoma; T size of the primary tumor and whether it has invaded nearby tissue

Table 3

Risk factors longer WIT in each period

Risk categoryOR95% CIp
Lower limitUpper limit
1st periodGenderMale6.1821.10134.7000.038
N36.5001.12734.4840.036
2nd periodTumor diameter (mm)33 ≤6.5001.53727.4860.011
N35.0001.09622.8200.038
Total score8 ≤4.6671.18718.3520.027
3rd periodL33.9001.00415.2760.044
Total score9 ≤2.4440.6549.1300.184

WIT warm ischemia time; OR odds ratio; CI confidence interval; N nearness of the tumor to the collecting system or sinus; L location relative to the polar lines

Patient characteristics IQR interquartile range; BMI body mass index; RENAL radius, exophytic/endophytic, nearness of tumor to collecting system, anterior/posterior, location relative to polar line; eGFR estimated glomerular filtration rate; POM postoperative month; T size of the primary tumor and whether it has invaded nearby tissue; TH high-volume surgeon in our hospital Surgical outcomes of robot-assisted partial nephrectomy HT high-volume surgeon in our hospital; eGFR estimated glomerular filtration rate; AML angiomyolipoma; MTSCC mucinous tubular and spindle cell carcinoma; T size of the primary tumor and whether it has invaded nearby tissue Risk factors longer WIT in each period WIT warm ischemia time; OR odds ratio; CI confidence interval; N nearness of the tumor to the collecting system or sinus; L location relative to the polar lines

Discussion

As the surgeon gained RALPN experience, the procedure was able to be used in more complex cases, such as patients with larger tumors and worse kidney function. However, the complication rate did not change throughout the study period. In the introductory period, male sex and a high RENAL N-component score were associated with longer WIT. In the intermediate period, a large tumor and high N-component and total RENAL scores were associated with longer WIT, but in the late period, only a high RENAL L-component score was associated. Over the past decade, robotics rapidly spread across all surgical fields, with tremendous innovation in urological surgeries [18]. Presently, robot techniques are routinely applied safely and effectively to urological operations. The success of RALPN may be primarily influenced by a surgeon’s experience and confidence. In this study, the indication for RALPN for RCC was influenced by tumor size during the early period [19]. However, as the surgeon’s experience with RALPN increased, the indication for RALPN expanded, eventually becoming the standard procedure for T1a and T1b RCC at our institution. Other studies have also reported similar data [20, 21]. In our early period, tumors < 4 cm in diameter were suitable for the robotic platform, but tumors > 4 cm in size were also treated with RALPN in the later periods. In period 3, 47% of tumors were stage cT1b (18/38; Table 1), and RALPN was performed by our institute’s most experienced surgeon. Furthermore, during the late period, patients with less kidney function, such as RCC in the solitary kidney, were also candidates for RALPN. Objectively evaluating the difficulty of a partial nephrectomy has been attempted ever since the introduction of the laparoscopic partial nephrectomy. The RENAL score is a well-validated method for this purpose and is used to evaluate RALPN patients. However, these scores are primarily validated from laparoscopic partial nephrectomies and may be inadequate for assessing robotic procedure difficulties [10, 22]. Nevertheless, each RENAL score component focused on representative points regarding the kidney tumor dissection. The N-component indicates the nearness of the tumor to the collecting system or sinus. For a less experienced surgeon, an open collecting system and a large vessel injury would be troublesome [23], potentially resulting in longer WIT during the early experience period. The L-component indicates the tumor location relative to the polar lines. A high L-component score included hilar tumors in patients with a large tumor. In our late period, most cases were considered highly complex tumors because of their large diameter (median, 39.5 mm), high N factor (median 3 [interquartile range 3-3]), and high total RENAL score (median, 8). In these complicated cases, a central tumor lesion affected WIT because a major parenchymal defect across a central kidney lesion is difficult to cope with. To suture between surgical margins, a deep suture is needed to avoid parenchymal fracture and postoperative hemorrhage. However, this suture potentially causes injury to major vessels and the collecting system [24]. Thus, careful suturing is required, resulting in longer WIT [25, 26]. Dissection and suturing skills evolve with increasing experience, and obtaining skills other than laparoscopic partial nephrectomy is a relatively rapid process. Zeuschner et al. reviewed RALPN outcomes and suggested that 35 cases were the minimum required number to acquire adequate RALPN skills [27]. The complication rate did not change throughout our study, which could be explained by the fact that the cases were carefully selected to match the surgeon’s skill during each period. In addition, the early unclamping technique may contribute to our stable WIT result [26]. Early unclamping allowed us for only focusing on the precise dissection of the tumor because this technique can provide information regarding arterial bleeding from the resected bed before renorrhaphy. Early unclamping significantly reduces the risk of asymptomatic unruptured pseudoaneurysm [27]. A pseudoaneurysm was the main complication in this study. As RALPN use increased, fewer pseudoaneurysm cases after laparoscopic partial nephrectomy were expected [28]. However, pseudoaneurysms remain at a low but constant rate in the robotic era [29]. In this study, all pseudoaneurysm cases were successfully managed by arterial embolization. Based on these findings derived and our study’s complication rate, we conclude that RALPN is a safe procedure. Our study had several limitations. First, this was a retrospective review of data from patients treated at a single institution, and multi-center, prospective studies are still needed. Second, WIT risk evaluation was only investigated by RENAL score-related factors and clinical factors and did not include C-index or PADUA score. Third, long-term follow-up of kidney function was lacking. Almost all of our WIT was less than 25 min, and it is uncertain if such a short WIT affects kidney function. Although this is not the first study on this topic, to our knowledge, ours is the first to assess WIT risk factors in complex patients. Furthermore, a single surgeon performed surgery on a sufficient number of patients, emphasizing the relevance of our study results.

Conclusions

RALPN is an effective and safe treatment that combines the advantages of a robotic platform with the standard oncological surgical strategies. A large tumor in the central lesion of a kidney may result in longer WIT, even when the procedure is performed by an experienced surgeon. Additional file 1: Supplement Table 1. Risk factor screening of the patients divided into three periods in chronological order.
  29 in total

1.  Technique and outcomes of robot-assisted retroperitoneoscopic partial nephrectomy: a multicenter study.

Authors:  Jim C Hu; Eric Treat; Christopher P Filson; Ian McLaren; Siwei Xiong; Sevan Stepanian; Khaled S Hafez; Alon Z Weizer; James Porter
Journal:  Eur Urol       Date:  2014-05-22       Impact factor: 20.096

2.  The Mayo Adhesive Probability Score Predicts Longer Dissection Time During Laparoscopic Partial Nephrectomy.

Authors:  Yuanxin Yao; Yansheng Xu; Liangyou Gu; Kan Liu; Pin Li; Yundong Xuan; Yu Gao; Xu Zhang
Journal:  J Endourol       Date:  2020-04-21       Impact factor: 2.942

3.  Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis.

Authors:  Kunihiro Matsushita; Marije van der Velde; Brad C Astor; Mark Woodward; Andrew S Levey; Paul E de Jong; Josef Coresh; Ron T Gansevoort
Journal:  Lancet       Date:  2010-05-17       Impact factor: 79.321

Review 4.  Current status of robotic surgery in urology.

Authors:  Masashi Honda; Shuichi Morizane; Katsuya Hikita; Atsushi Takenaka
Journal:  Asian J Endosc Surg       Date:  2017-09-14

5.  Are renal tumour scoring systems better than clinical judgement at predicting partial nephrectomy complexity?

Authors:  Ravi M Kumar; Luke T Lavallée; Darren Desantis; Sonya Cnossen; Ranjeeta Mallick; Ilias Cagiannos; Chris Morash; Rodney H Breau
Journal:  Can Urol Assoc J       Date:  2017-06       Impact factor: 1.862

6.  The comparison of three renal tumor scoring systems: C-Index, P.A.D.U.A., and R.E.N.A.L. nephrometry scores.

Authors:  Zhamshid Okhunov; Soroush Rais-Bahrami; Arvin K George; Nikhil Waingankar; Brian Duty; Sylvia Montag; Lisa Rosen; Suzanne Sunday; Manish A Vira; Louis R Kavoussi
Journal:  J Endourol       Date:  2011-09-09       Impact factor: 2.942

7.  Kidney ventrally rotation technique in retroperitoneal robot-assisted partial nephrectomy for posterior hilar tumor: technical feasibility and preliminary results.

Authors:  Xiaotao Yin; Sinan Jiang; Zhiqiang Shao; Yongliang Lu; Jiaxiang Guo; Yi Xiao; Xiaoying Zhu; Hualiang Yu; Han Ma; Yu Yang; Jiangping Gao
Journal:  World J Surg Oncol       Date:  2020-06-30       Impact factor: 2.754

8.  Three Different Learning Curves Have an Independent Impact on Perioperative Outcomes After Robotic Partial Nephrectomy: A Comparative Analysis.

Authors:  Philip Zeuschner; Irmengard Meyer; Stefan Siemer; Michael Stoeckle; Gudrun Wagenpfeil; Stefan Wagenpfeil; Matthias Saar; Martin Janssen
Journal:  Ann Surg Oncol       Date:  2020-07-24       Impact factor: 5.344

9.  Robot-assisted Partial Nephrectomy: 5-yr Oncological Outcomes at a Single European Tertiary Cancer Center.

Authors:  Mihai Dorin Vartolomei; Deliu Victor Matei; Giuseppe Renne; Valeria Maria Tringali; Nicolae Crisan; Gennaro Musi; Francesco Alessandro Mistretta; Andrea Russo; Gabriele Cozzi; Giovani Cordima; Stefano Luzzago; Antonio Cioffi; Ettore Di Trapani; Michele Catellani; Maurizio Delor; Danilo Bottero; Ciro Imbimbo; Vincenzo Mirone; Matteo Ferro; Ottavio de Cobelli
Journal:  Eur Urol Focus       Date:  2017-10-27

10.  Trifecta Outcomes to Assess Learning Curve of Robotic Partial Nephrectomy.

Authors:  Olamide O Omidele; Natan Davoudzadeh; Michael Palese
Journal:  JSLS       Date:  2018 Jan-Mar       Impact factor: 2.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.